TY  - JOUR
A1  - Cavagna, Lorenzo
A1  - Trallero-Araguás, Ernesto
A1  - Meloni, Federica
A1  - Cavazzana, Ilaria
A1  - Rojas-Serrano, Jorge
A1  - Feist, Eugen
A1  - Zanframundo, Giovanni
A1  - Morandi, Valentina
A1  - Meyer, Alain
A1  - Silva, José António Pereira da
A1  - Matos Costa, Carlo Jorge
A1  - Molberg, Oyvind
A1  - Andersson, Helena
A1  - Codullo, Veronica
A1  - Mosca, Marta
A1  - Barsotti, Simone
A1  - Neri, Rossella
A1  - Scirè, Carlo Alberto
A1  - Govoni, Marcello
A1  - Furini, Federica
A1  - López-Longo, Francisco Javier
A1  - Martínez-Barrio, Julia
A1  - Schneider, Udo
A1  - Lorenz, Hanns-Martin
A1  - Doria, Andrea
A1  - Ghirardello, Anna
A1  - Ortego-Centeno, Norberto
A1  - Confalonieri, Marco
A1  - Tomietto, Paola
A1  - Pipitone, Nicolò
A1  - Rodriguez Cambron, Ana Belen
A1  - Blázquez Cañamero, María Ángeles
A1  - Voll, Reinhard
A1  - Wendel, Sarah
A1  - Scarpato, Salvatore
A1  - Maurier, Francois
A1  - Limonta, Massimiliano
A1  - Colombelli, Paolo
A1  - Giannini, Margherita
A1  - Geny, Bernard
A1  - Arrigoni, Eugenio
A1  - Bravi, Elena
A1  - Migliorini, Paola
A1  - Mathieu, Alessandro
A1  - Piga, Matteo
A1  - Drott, Ulrich
A1  - Delbrück, Christiane
A1  - Bauhammer, Jutta
A1  - Cagnotto, Giovanni
A1  - Vancheri, Carlo
A1  - Sambataro, Gianluca
A1  - De Langhe, Ellen
A1  - Sainaghi, Pier Paolo
A1  - Monti, Cristina
A1  - Berzolari, Francesca Gigli
A1  - Romano, Mariaeva
A1  - Bonella, Francesco
A1  - Specker, Christof
A1  - Schwarting, Andreas
A1  - Villa Blanco, Ignacio
A1  - Selmi, Carlo
A1  - Ceribelli, Angela
A1  - Nuno, Laura
A1  - Mera-Varela, Antonio
A1  - Gomez, Nair Perez
A1  - Fusaro, Enrico
A1  - Parisi, Simone
A1  - Sinigaglia, Luigi
A1  - Del Papa, Nicoletta
A1  - Benucci, Maurizio
A1  - Cimmino, Marco Amedeo
A1  - Riccieri, Valeria
A1  - Conti, Fabrizio
A1  - Sebastiani, Gian Domenico
A1  - Iuliano, Annamaria
A1  - Emmi, Giacomo
A1  - Cammelli, Daniele
A1  - Sebastiani, Marco
A1  - Manfredi, Andreina
A1  - Bachiller Corral, Javier
A1  - Sifuentes Giraldo, Walter Alberto
A1  - Paolazzi, Giuseppe
A1  - Saketkoo, Lesley Ann
A1  - Giorgi, Roberto
A1  - Salaffi, Fausto
A1  - Cifrian, Jose
A1  - Caporali, Roberto
A1  - Locatelli, Francesco
A1  - Marchioni, Enrico
A1  - Pesci, Alberto
A1  - Dei, Giulia
A1  - Pozzi, Maria Rosa
A1  - Claudia, Lomater
A1  - Distler, Jörg Hans Wilhelm
A1  - Knitza, Johannes
A1  - Schett, George
A1  - Iannone, Florenzo
A1  - Fornaro, Marco
A1  - Franceschini, Franco
A1  - Quartuccio, Luca
A1  - Gerli, Roberto
A1  - Bartoloni, Elena
A1  - Bellando-Randone, Silvia
A1  - Zampogna, Giuseppe
A1  - Gonzalez Perez, Montserrat I.
A1  - Mejia, Mayra
A1  - Vicente, Esther
A1  - Triantafyllias, Konstantinos
A1  - López-Mejias, Raquel
A1  - Matucci-Cerinic, Marco
A1  - Selva-O’Callaghan, Albert
A1  - Castañeda, Santos
A1  - Montecucco, Carlomaurizio
A1  - González-Gay, Miguel Ángel
T1  - Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course
T2  - Journal of Clinical Medicine
N2  - Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.
KW  - antisynthetase syndrome
KW  - antisynthetase antibodies
KW  - arthritis
KW  - myositis
KW  - interstitial lung disease
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53555
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-535550
SN  - 2077-0383
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
VL  - 8
IS  - 11, Art. 2013
SP  - 1
EP  - 13
PB  - MDPI
CY  - Basel
ER  -